CA2092505A1 - Pharmaceutical compositions containing l-carnitine or an acyl l-carnitine in combination with an ace-inhibitor for the treatment of cardiovascular disorders and a method for treating cardiovascular disorders - Google Patents

Pharmaceutical compositions containing l-carnitine or an acyl l-carnitine in combination with an ace-inhibitor for the treatment of cardiovascular disorders and a method for treating cardiovascular disorders

Info

Publication number
CA2092505A1
CA2092505A1 CA002092505A CA2092505A CA2092505A1 CA 2092505 A1 CA2092505 A1 CA 2092505A1 CA 002092505 A CA002092505 A CA 002092505A CA 2092505 A CA2092505 A CA 2092505A CA 2092505 A1 CA2092505 A1 CA 2092505A1
Authority
CA
Canada
Prior art keywords
carnitine
cardiovascular disorders
ace
acyl
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002092505A
Other languages
French (fr)
Other versions
CA2092505C (en
Inventor
Claudio Cavazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CA2092505A1 publication Critical patent/CA2092505A1/en
Application granted granted Critical
Publication of CA2092505C publication Critical patent/CA2092505C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Compositions containing (a) L-carnitine, an acyl L-carnite, or a pharmacologically acceptable salt thereof in combination with (b) an ACE-inhibiter are useful for treating cardiovascular disorders. Orraly, parenterally, rectally or transdernally administrable pharmaceutical composition in unit form contain from about 0.8 to about 2 g of L-carnitine, or an equinolar amount of an aoyl L-carnitine or a pharnaoologically acceptable salt thereof, and, e.g., from about 5 to about 20 mg of the ACE-inhibitor lisinopril.
CA002092505A 1992-03-27 1993-03-25 Pharmaceutical compositions containing l-carnitine or an acyl l-carnitine in combination with an ace-inhibitor for the treatment of cardiovascular disorders and a method for treating cardiovascular disorders Expired - Lifetime CA2092505C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM920222A IT1254314B (en) 1992-03-27 1992-03-27 PHARMACEUTICAL COMPOSITIONS CONTAINING L-CARNITINE AND ACYL-CARNITINE ASSOCIATION WITH ACE-INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES.
ITRM92A000222 1992-03-27

Publications (2)

Publication Number Publication Date
CA2092505A1 true CA2092505A1 (en) 1993-09-28
CA2092505C CA2092505C (en) 2004-06-01

Family

ID=11400880

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002092505A Expired - Lifetime CA2092505C (en) 1992-03-27 1993-03-25 Pharmaceutical compositions containing l-carnitine or an acyl l-carnitine in combination with an ace-inhibitor for the treatment of cardiovascular disorders and a method for treating cardiovascular disorders

Country Status (11)

Country Link
US (1) US5861434A (en)
EP (1) EP0566542B1 (en)
JP (1) JP3616116B2 (en)
KR (1) KR100244092B1 (en)
AT (1) ATE165241T1 (en)
CA (1) CA2092505C (en)
DE (1) DE69318061T2 (en)
DK (1) DK0566542T3 (en)
ES (1) ES2116429T3 (en)
HK (1) HK1009325A1 (en)
IT (1) IT1254314B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2733911B1 (en) * 1995-05-09 1998-05-29 Takeda Chemical Industries Ltd PHARMACEUTICAL COMPOSITION FOR RENAL OR CARDIOVASCULAR DISEASES
IT1277953B1 (en) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti PHARMACEUTICAL COMPOSITION CONTAINING L-CARNITINE OR AN ALCANOYL L-CARNITINE AND A 3-OMEGA SERIES POLYUNSATURED ACID USEFUL
IT1284661B1 (en) * 1996-06-06 1998-05-21 Sigma Tau Ind Farmaceuti USE OF ALCANOIL L-CARNITINE IN THE THERAPEUTIC TREATMENT OF CHRONIC INTESTINAL INFLAMMATORY DISEASES.
SI0951909T2 (en) 1998-03-19 2010-11-30 Sigma Tau Ind Farmaceuti Combination composition comprising a L-carnitine or an alkanoyl-L-carnitine, a glycosaminoglycan and/or constituent thereof
LV12491B (en) * 1998-10-29 2000-12-20 Ivars KALVIŅŠ Pharmaceutical composition
WO2000027387A1 (en) * 1998-11-11 2000-05-18 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis
US20030206895A1 (en) * 1998-11-13 2003-11-06 Sigma-Tau Healthscience S.P.A. Antioxidant composition comprising propionyl L-carnitine and a flavonoid against throm-bosis and atherosclerosis
IT1306722B1 (en) * 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF CIRCULATORY DYSFUNCTIONS, INCLUDING L-CARNITINE DERIVATIVES AND EXTRACTS OF
BR0017074A (en) * 2000-01-26 2002-12-03 Warner Lambert Co Combinations of vasopressin ace-antagonist inhibitor
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
SI2136798T1 (en) * 2007-03-21 2015-10-30 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance
KR101179421B1 (en) * 2009-02-18 2012-09-05 레이스팬 코포레이션 Metamaterial Power Amplifier System

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU518617B2 (en) * 1977-04-29 1981-10-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Therapeutic application of acetyl-d, 1-carnitine
CH655005A5 (en) * 1983-02-16 1986-03-27 Sigma Tau Ind Farmaceuti PHARMACEUTICAL COMPOSITION WITH METABOLIC AND ENERGY ACTION USABLE IN CARDIAC AND VASCULAR THERAPY.
US5025001A (en) * 1988-06-15 1991-06-18 Brigham And Women's Hospital S-nitroso derivatives of ACE inhibitors and the use thereof
IT1235153B (en) * 1988-11-15 1992-06-22 Sigma Tau Ind Farmaceuti USE OF ACETYL L-CARNITINE IN THE THERAPEUTIC TREATMENT OF CATARACT AND PHARMACEUTICAL COMPOSITIONS USEFUL IN SUCH TREATMENT
IT1224795B (en) * 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti USE OF ACETYL D-CARNITINE IN THE THERAPEUTIC TREATMENT OF GLAUCOMA AND PHARMACEUTICAL COMPOSITIONS USEFUL IN SUCH TREATMENT
IT1224842B (en) * 1988-12-27 1990-10-24 Sigma Tau Ind Farmaceuti USE OF L-CARNITINE DERIVATIVES IN THE THERAPEUTIC TREATMENT OF DEGENERATIVE ALTERATIONS OF THE NERVOUS SYSTEM
IT1240799B (en) * 1990-03-15 1993-12-17 Sigma Tau Ind Farmaceuti PHARMACEUTICAL COMPOSITIONS CONTAINING 3-METHYLTHIOPROPIONYL L-CARNITINE FOR ACTIVITY ON THE CARDIOVASCULAR SYSTEM.
IT1244636B (en) * 1991-01-04 1994-08-08 Sigma Tau Ind Farmaceuti USE OF ACETYL L-CARNITINE IN THERAPEUTIC TREATMENT OF COMA AND PHARMACEUTICAL COMPOSITIONS USEFUL IN SUCH TREATMENT.
IT1248323B (en) * 1991-05-16 1995-01-05 Sigma Tau Ind Farmaceuti STARCHES WITH NATURAL AMINO ACIDS OF ALCANOIL L-CARNITINE AS INHIBITORS OF THE NEURONAL DEGENERATION AND ACTIVATORS OF THE LEARNING AND STORING PROCESSES AND FOR THE TREATMENT OF THE COMA AND PHARMACEUTICAL COMPOSITIONS INCLUDING SUCH COMPOUNDS
IT1245699B (en) * 1991-05-29 1994-10-14 Sigma Tau Ind Farmaceuti L-CARNITINE DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF MYOPATHIES, NEURONAL DEGENARATION AND TO INHIBIT PROTEOLYSIS

Also Published As

Publication number Publication date
US5861434A (en) 1999-01-19
ES2116429T3 (en) 1998-07-16
DE69318061D1 (en) 1998-05-28
EP0566542B1 (en) 1998-04-22
CA2092505C (en) 2004-06-01
DK0566542T3 (en) 1999-01-04
IT1254314B (en) 1995-09-14
KR930019208A (en) 1993-10-18
DE69318061T2 (en) 1998-08-13
EP0566542A1 (en) 1993-10-20
HK1009325A1 (en) 1999-05-28
ITRM920222A0 (en) 1992-03-27
JPH0616570A (en) 1994-01-25
ITRM920222A1 (en) 1993-09-27
ATE165241T1 (en) 1998-05-15
KR100244092B1 (en) 2000-03-02
JP3616116B2 (en) 2005-02-02

Similar Documents

Publication Publication Date Title
CA2258920A1 (en) Autocross-linked hyaluronic acid and related pharmaceutical compositions for the treatment of arthropathies
HUT72888A (en) Pharmaceutical compositions comprising carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
EP0693928A4 (en) Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue
BG103793A (en) COMBINED THERAPY USING BENZOTHIAPINS INHIBITING THE ILEAL BILE ACID TRANSPORT AND HMG Co-A REDUCTASE INHIBITORS
CA2081604A1 (en) Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
GB9410987D0 (en) High dosage pharmaceutical compositions
CA2233457A1 (en) Pharmaceutical angiostatic dipeptide compositions and methods of use thereof
HUP9601419A3 (en) Synergetic pharmaceutical compositions for treating parkinson-disease
IL125735A0 (en) Pharmaceutical compositions for the treatment of glaucoma
CA2092505A1 (en) Pharmaceutical compositions containing l-carnitine or an acyl l-carnitine in combination with an ace-inhibitor for the treatment of cardiovascular disorders and a method for treating cardiovascular disorders
PL316528A1 (en) Pharmaceutic compositions and drugs for prevetion and treatment of endothelial disorders
IL117656A0 (en) Pharmaceutical compositions for the treatment of travellers diarrhea
AU1430492A (en) Pharmaceutical composition for the treatment of gastritis
HUP9903459A3 (en) Oxa- and tiabicyclo[3.1.0]hexane-carboxylic acids, process for their preparation and pharmaceutical compositions of the same
IL117655A0 (en) Pharmaceutical compositions for the treatment of travellers diarrhea
IL112024A0 (en) Pharmaceutical compositions for treating gastointestinal motility disorders
AU7812794A (en) Pharmaceutical compositions containing n-acetylcarnosine for the treatment of cataract
JPS57126420A (en) Drug for digestive organ
AU5963396A (en) Cis-resorcylide, pharmaceutical composition containing it, use thereof in the treatment of thrombosis and related disorders
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
CA2061907A1 (en) Treatment of ocular hypertension with a synergistic combination
IL101441A0 (en) Pharmaceutical compositions for the treatment and/or prevention of degenerative disorders in the retina
ZA947924B (en) Heteroarylpiperidines process for their preparation and pharmaceutical compositions in which they are present
IL105690A0 (en) Pharmaceutical compositions for the treatment of arrhythmia
GB2316614B (en) Composition for a dietary supplement for the treatment of hemorrhoids

Legal Events

Date Code Title Description
EEER Examination request